Addition of Atezolizumab to FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
Recommended
Addition of Atezolizumab to FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
The addition of atezolizumab to FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, irinotecan) and bevacizumab improved progression-free survival in the first-line treatment of patients with metastatic colorectal cancer.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->